Grifols, a global healthcare company and manufacturer of plasma-derived medicines, has entered into a collaboration with FcR Therapeutics, a biotechnology start-up, to develop recombinant nanobodies to treat autoimmune diseases.

Through the collaboration, Grifols will support in seeding the work of FcR Therapeutics, based in Utrecht, the Netherlands, in addition to contributing its expertise in immunoglobulins, the human immune system and recombinant proteins.

Immunoglobulins and their immunomodulatory effects normally help treat autoimmune diseases such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), immune thrombocytopenic purpura (ITP) and Guillain-Barré Syndrome (GBS).